Drug Trial Radar · NCT06379789
A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B
Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
130
Planned (sponsor's estimate)
Start
Sep 11, 2024
Primary completion
Aug 14, 2034
Study completion Aug 14, 2047
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Intellia Therapeutics
- First posted
- Apr 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Participants in this study have a genetic mutation, specifically in the coagulation (blood clotting) Factor 9 gene that causes severe or moderately severe hemophilia B. This study is researching an experimental gene insertion therapy (the adding of a gene into your DNA) called REGV131-LNP1265, also called the "study drug". Gene insertion therapy aims to teach the body how to produce clotting factor long-term, without the need for factor replacement therapy. The main aim of this study is to find a safe and well-tolerated dose of the study drug by checking the side effects that may happen from taking it, both in the near term and over time. The study is looking at several other research questions including: * How much study drug is in the blood at different times * Whether the body makes antibodies against parts of the study drug, which could make the drug less effective or could lead to side effects. Antibodies are proteins produced by the body's immune system in response to a foreign substance * Whether the body makes antibodies against the clotting factor replacement therapy * How often factor replacement therapy is needed, both on a regular basis for prevention of bleeding, and as needed to treat bleeding events (and it if changes after taking study drug) * Whether there is a difference in 2 different methods for measuring Factor 9 activity in the blood
Conditions
- Hemophilia B
Interventions
REGV131Drug
Administered per the protocol before LNP1265
LNP1265Drug
Administered per the protocol following REGV131
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to 2 Years
- Severity of TEAEsTime frame: Up to 2 Years
- Coagulation Factor IX (FIX) functional activity measured using the chromogenic substrate assayTime frame: Up to 2 Years
- Change in FIX functional activity in plasma, measured using the chromogenic substrate assayTime frame: Up to 2 Years
- Annualized Bleeding Rate (ABR) following sustained FIX functional activity among participants receiving the RDETime frame: Up to 2 Years
- Occurrence of Serious Adverse Events (SAEs)Time frame: Through Long Term Follow Up (LTFU), Up to 15 Years
- Severity of SAEsTime frame: Through LTFU, Up to 15 Years
- Occurrence of Adverse Event of Special Interests (AESIs)Time frame: Through LTFU, Up to 15 Years
- Severity of AESIsTime frame: Through LTFU, Up to 15 Years
- Occurrence of clinically meaningful Adverse Events (AEs)Time frame: Through LTFU, Up to 15 Years
- Severity of clinically meaningful AEsTime frame: Through LTFU, Up to 15 Years
Locations
54 sites in 9 countries. Site status is shown where the registry gives one.
Phoenix Children's Hospital
Phoenix, Arizona · Recruiting
Orthopaedic Hemophilia Treatment Center
Los Angeles, California · Recruiting
David Geffen School of Medicine at UCLA
Los Angeles, California · Recruiting
Children's Hospital Los Angeles
Los Angeles, California · Recruiting
University of California Davis
Sacramento, California · Recruiting
University California San Francisco
San Francisco, California · Recruiting
University of Colorado Hemophilia and Thrombosis Center
Aurora, Colorado · Recruiting
Yale HTC
New Haven, Connecticut · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Indiana Hemophilia and Thrombosis Center
Indianapolis, Indiana · Recruiting
Tulane University School of Medicine, Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana · Recruiting
University of Michigan
Ann Arbor, Michigan · Recruiting
Nationwide Children's Hospital
Columbus, Ohio · Recruiting
Children's Hospital of Philadelphia (CHOP)
Philadelphia, Pennsylvania · Recruiting
Hemophilia Center of Western Pennsylvania
Pittsburgh, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Children's Medical Center Dallas
Dallas, Texas · Recruiting
University of Texas Health Science Center at Houston
Houston, Texas · Recruiting
Royal Prince Alfred Hospital, Haemophilia Treatment Centre
Camperdown, New South Wales, Australia · Recruiting
Royal Brisbane and Women's Hospital
Herston, Queensland, Australia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Recruiting
Alfred Hospital
Melbourne, Victoria, Australia · Recruiting
Hemorio
Rio de Janeiro, Brazil · Recruiting
Centro Estadual de Hemoterapia e Hematologia Marcos Daniel Santos
Vitória, Espírito Santo, Brazil · Recruiting
Hemocentro Unicamp
Campinas, São Paulo, Brazil · Recruiting
University of Alberta Hospital
Edmonton, Alberta, Canada · Recruiting
McMaster University Medical Centre - Hamilton Health Sciences
Hamilton, Ontario, Canada · Recruiting
McGill University Health Center (MUHC)
Montreal, Quebec, Canada · Recruiting
Hopital Necker
Paris, Île-de-France Region, France · Recruiting
Hospices Civils de Lyon
Bron, Lyon, France · Recruiting
Hemostase Clinique, Institut Coeur Poumon
Lille, Nord, France · Recruiting
University Hospital Hamburg Eppendorf
Hamburg, Germany · Recruiting
University Hospital Frankfurt
Frankfurt am Main, Hesse, Germany · Recruiting
University Clinic Bonn, Institute of Experimental Haematology and Transfusion Medicine
Bonn, North Rhine-Westphalia, Germany · Recruiting
Ospedale san Bortolo
Vicenza, Italy · Recruiting
Careggi University Hospital
Florence, Firenze, Italy · Recruiting
Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Ca Granda Ospedale Maggiore Policlinico
Milan, Lombardy, Italy · Recruiting
Irccs Humanitas Research Hospital
Rozzano, Lombardy, Italy · Recruiting
Hospital Universitario Vall d'Hebron
Barcelona, Spain · Recruiting
Hospital Universitario La Paz
Madrid, Spain · Recruiting
Showing 40 of 54 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.